The loss of Veracyte under GAAP for the 3 months of 2022 was $14.461 million, down 2.9 times from $41.868 million in the previous year. Revenue increased 84.7% to $67.783 million from $36.703 million a year earlier.

Veracyte's GAAP loss for 2021 was $75.563 million, up 2.2 times from $34.909 million in the previous year. Revenue increased 86.8% to $219.514 million from $117.483 million a year earlier.

Veracyte's GAAP loss for 9M 2021 was $65.035 million, up 2.4 times from $26.865 million in the previous year. Revenue increased 83.5% to $152.178 million from $82.947 million a year earlier.

Veracyte's GAAP loss for the six months of 2021 was $50.906 million, up 2.2 times from $22.741 million in the previous year. Revenue increased 77.1% to $91.808 million from $51.826 million a year earlier.